Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;32(8):e22579.
doi: 10.1002/jcla.22579. Epub 2018 Jun 21.

Prevalence of combined and noncombined dyslipidemia in an Iranian population

Susan Darroudi  1 , Maryam Saberi-Karimian  1 , Maryam Tayefi  2   3 , Soheil Arekhi  4   5 , Ali Motamedzadeh Torghabeh  4 , Seyed Mohammad Reza Seyedzadeh Sani  4 , Mohsen Moohebati  6 , Alireza Heidari-Bakavoli  6 , Mahmoud Ebrahimi  6 , Mahmoud Reza Azarpajouh  6 , Mohammad Safarian  7 , Gordon A Ferns  8 , Habibollah Esmaeili  8 , Mohammad Reza Parizadeh  3   7 , Naghme Mokhber  6 , Adeleh Mahdizadeh  6 , Ali Asghar Mahmoudi  9 , Amir Hossein Sahebkar  10   11   12 , Majid Ghayour-Mobarhan  6
Affiliations

Prevalence of combined and noncombined dyslipidemia in an Iranian population

Susan Darroudi et al. J Clin Lab Anal. 2018 Oct.

Abstract

Background: Combination of dyslipidemic phenotypes, including elevated plasma levels of low-density lipoprotein cholesterol (LDL-C), elevated plasma triglycerides (TG), and decreased low-density lipoprotein cholesterol (HDL-C) concentrations, is important because of the association of individual phenotypes with increased risk of cardiovascular disease (CVD). We investigated the prevalence of combined dyslipidemias and their effects on CVD risk in an Iranian large population.

Method: A total of 9847 individuals were recruited as part of the Mashhad Stroke and Heart Atherosclerotic Disorders (MASHAD) cohort study. Anthropometric parameters and biochemical indices were measured in all of the subjects. Different types of combined dyslipidemias including high TG + low HDL-C, high TG + low HDL-C + high LDL-C, low HDL-C + high LDL-C, high TG + high LDL-C, and finally high TG + high LDL-C + low HDL-C were considered. Ten-year CVD risk was calculated using the QRISK2 risk algorithm and adjustments were made as suggested by the Joint British Societies' (JBS2). Logistic regression analyses were performed to determine the association between different combined dyslipidemias and categorical QRISK.

Results: A total of 3952 males and 5895 females were included in this current study. Among the included subjects, 83.4% had one form of dyslipidemia, and 16.6% subjects were not dyslipidemic. The mean age was 48.88 ± 7.9 and 47.02 ± 8.54 years for dyslipidemic and nondyslipidemic groups, respectively. The results showed that the frequency of dyslipidemia was 98%, 87.1%, and 90% in subjects with metabolic syndrome, CVD, and diabetes, respectively. Our results suggested that around 15.7% of study population were at 10 years CVD risk (high ≥20) and it was higher in men than women (P < .001). Moreover, risk of CVD was higher in TG↑ & HDL↓ & LDL↑ group than other groups.

Conclusion: Prevalence of dyslipidemia was 83.4% among Iranian adults. The results showed that individuals with increased plasma TG and LDL-C, and low HDL-C levels had the highest 10 years CVD risk compared to other combined dyslipidemic phenotypes.

Keywords: Iran; cardiovascular disease; diabetes mellitus; dyslipidemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phenotype of combine dyslipidemia*, *P < .05
Figure 2
Figure 2
10 years cardiovascular disease (CVD) risk according phenotype of combined and noncombined dyslipidemia*, *P < .05
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. National Institutes of Health, National Heart Lung, Blood Institute . Atp iii guidelines at‐a‐glance quick desk reference. NIH publication 2001.
    1. Mohammadbeigi A, Moshiri E, Mohammadsalehi N, Ansari H, Ahmadi A. Dyslipidemia prevalence in Iranian adult men: the impact of population‐based screening on the detection of undiagnosed patients. World J Mens Health. 2015;33:167‐173. - PMC - PubMed
    1. Tabatabaei‐Malazy O, Qorbani M, Samavat T, Sharifi F, Larijani B, Fakhrzadeh H. Prevalence of dyslipidemia in Iran: a systematic review and meta‐analysis study. Int J Prev Med. 2014;5:373. - PMC - PubMed
    1. Taheri F, Chahkandi T, Kazemi T, Bijari B, Zardast M, Namakin K. Lipid profiles and prevalence of dyslipidemia in eastern Iranian adolescents, Birjand, 2012. Iran J Med Sci. 2015;40:341. - PMC - PubMed
    1. Rizzo M, Barylski M, Rizvi AA, Montalto G, Mikhailidis DP, Banach M. Combined dyslipidemia: should the focus be ldl cholesterol or atherogenic dyslipidemia? Curr Pharm Des. 2013;19:3858‐3868. - PubMed